vs
Side-by-side financial comparison of ESSENTIAL PROPERTIES REALTY TRUST, INC. (EPRT) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
ESSENTIAL PROPERTIES REALTY TRUST, INC. is the larger business by last-quarter revenue ($158.8M vs $86.8M, roughly 1.8× IOVANCE BIOTHERAPEUTICS, INC.). On growth, ESSENTIAL PROPERTIES REALTY TRUST, INC. posted the faster year-over-year revenue change (22.8% vs 17.7%). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 20.6%).
Essential Properties Realty Trust is a publicly traded real estate investment trust (REIT) that acquires, owns and manages a diversified portfolio of single-tenant net-leased commercial properties across the United States. Its assets primarily cover essential service-oriented sectors including casual dining, automotive services, medical clinics, early childhood education centers and light industrial facilities, with tenants mostly holding robust long-term operating track records.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
EPRT vs IOVA — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $158.8M | $86.8M |
| Net Profit | $60.0M | — |
| Gross Margin | — | 67.4% |
| Operating Margin | 56.5% | -84.7% |
| Net Margin | 37.8% | — |
| Revenue YoY | 22.8% | 17.7% |
| Net Profit YoY | 6.5% | — |
| EPS (diluted) | $0.28 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $158.8M | — | ||
| Q4 25 | $149.9M | $86.8M | ||
| Q3 25 | $144.9M | $67.5M | ||
| Q2 25 | $137.1M | $60.0M | ||
| Q1 25 | $129.4M | $49.3M | ||
| Q4 24 | $119.7M | $73.7M | ||
| Q3 24 | $117.1M | $58.6M | ||
| Q2 24 | $109.3M | $31.1M |
| Q1 26 | $60.0M | — | ||
| Q4 25 | $68.1M | — | ||
| Q3 25 | $65.6M | $-91.3M | ||
| Q2 25 | $63.2M | $-111.7M | ||
| Q1 25 | $56.1M | $-116.2M | ||
| Q4 24 | $55.4M | — | ||
| Q3 24 | $49.1M | $-83.5M | ||
| Q2 24 | $51.5M | $-97.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | 67.4% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | — | 46.2% | ||
| Q2 24 | — | -0.8% |
| Q1 26 | 56.5% | — | ||
| Q4 25 | 65.9% | -84.7% | ||
| Q3 25 | 64.7% | -140.7% | ||
| Q2 25 | 64.1% | -189.8% | ||
| Q1 25 | 61.6% | -245.8% | ||
| Q4 24 | 66.1% | -117.5% | ||
| Q3 24 | 59.7% | -152.1% | ||
| Q2 24 | 61.1% | -327.6% |
| Q1 26 | 37.8% | — | ||
| Q4 25 | 45.4% | — | ||
| Q3 25 | 45.3% | -135.3% | ||
| Q2 25 | 46.1% | -186.2% | ||
| Q1 25 | 43.4% | -235.5% | ||
| Q4 24 | 46.3% | — | ||
| Q3 24 | 42.0% | -142.7% | ||
| Q2 24 | 47.1% | -312.2% |
| Q1 26 | $0.28 | — | ||
| Q4 25 | $0.34 | — | ||
| Q3 25 | $0.33 | — | ||
| Q2 25 | $0.32 | $-0.33 | ||
| Q1 25 | $0.29 | $-0.36 | ||
| Q4 24 | $0.31 | $-0.24 | ||
| Q3 24 | $0.27 | $-0.28 | ||
| Q2 24 | $0.29 | $-0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $15.2M | $297.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.4B | $698.6M |
| Total Assets | $7.2B | $913.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $15.2M | — | ||
| Q4 25 | $60.2M | $297.0M | ||
| Q3 25 | $23.8M | $300.8M | ||
| Q2 25 | $20.8M | $301.2M | ||
| Q1 25 | $47.0M | $359.7M | ||
| Q4 24 | $40.7M | $323.8M | ||
| Q3 24 | $32.7M | $397.5M | ||
| Q2 24 | $23.6M | $412.5M |
| Q1 26 | — | — | ||
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.3B | — | ||
| Q1 25 | $2.1B | — | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | $2.2B | — | ||
| Q2 24 | $1.9B | — |
| Q1 26 | $4.4B | — | ||
| Q4 25 | $4.2B | $698.6M | ||
| Q3 25 | $3.8B | $702.3M | ||
| Q2 25 | $3.8B | $698.5M | ||
| Q1 25 | $3.8B | $767.9M | ||
| Q4 24 | $3.6B | $710.4M | ||
| Q3 24 | $3.2B | $773.5M | ||
| Q2 24 | $3.2B | $768.5M |
| Q1 26 | $7.2B | — | ||
| Q4 25 | $6.9B | $913.2M | ||
| Q3 25 | $6.6B | $904.9M | ||
| Q2 25 | $6.3B | $907.4M | ||
| Q1 25 | $6.1B | $966.7M | ||
| Q4 24 | $5.8B | $910.4M | ||
| Q3 24 | $5.5B | $991.1M | ||
| Q2 24 | $5.3B | $964.3M |
| Q1 26 | — | — | ||
| Q4 25 | 0.60× | — | ||
| Q3 25 | 0.69× | — | ||
| Q2 25 | 0.61× | — | ||
| Q1 25 | 0.56× | — | ||
| Q4 24 | 0.60× | — | ||
| Q3 24 | 0.69× | — | ||
| Q2 24 | 0.59× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-52.6M |
| Free Cash FlowOCF − Capex | — | $-61.9M |
| FCF MarginFCF / Revenue | — | -71.3% |
| Capex IntensityCapex / Revenue | — | 10.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $381.1M | $-52.6M | ||
| Q3 25 | $99.0M | $-78.7M | ||
| Q2 25 | $99.8M | $-67.4M | ||
| Q1 25 | $77.2M | $-103.7M | ||
| Q4 24 | $308.5M | $-73.3M | ||
| Q3 24 | $73.5M | $-59.0M | ||
| Q2 24 | $81.1M | $-98.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | $-61.9M | ||
| Q3 25 | — | $-89.5M | ||
| Q2 25 | — | $-74.9M | ||
| Q1 25 | — | $-109.9M | ||
| Q4 24 | — | $-77.5M | ||
| Q3 24 | — | $-61.3M | ||
| Q2 24 | — | $-98.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | -71.3% | ||
| Q3 25 | — | -132.7% | ||
| Q2 25 | — | -124.9% | ||
| Q1 25 | — | -222.8% | ||
| Q4 24 | — | -105.1% | ||
| Q3 24 | — | -104.6% | ||
| Q2 24 | — | -317.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | 10.7% | ||
| Q3 25 | — | 16.1% | ||
| Q2 25 | — | 12.4% | ||
| Q1 25 | — | 12.6% | ||
| Q4 24 | — | 5.7% | ||
| Q3 24 | — | 3.9% | ||
| Q2 24 | — | 1.4% |
| Q1 26 | — | — | ||
| Q4 25 | 5.60× | — | ||
| Q3 25 | 1.51× | — | ||
| Q2 25 | 1.58× | — | ||
| Q1 25 | 1.38× | — | ||
| Q4 24 | 5.57× | — | ||
| Q3 24 | 1.50× | — | ||
| Q2 24 | 1.57× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EPRT
| Rental revenue 1,2 | $149.4M | 94% |
| Other | $8.6M | 5% |
| Other revenue | $779.0K | 0% |
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
